Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
Top Cited Papers
- 14 August 2014
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 384 (9959), 2046-2052
- https://doi.org/10.1016/s0140-6736(14)61185-5
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Longitudinal Analysis of the Human Antibody Response to Chikungunya Virus Infection: Implications for Serodiagnosis and Vaccine DevelopmentJournal of Virology, 2012
- Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical ProtectionThe Journal of Infectious Diseases, 2012
- Persistent Arthralgia Induced by Chikungunya Virus Infection is Associated with Interleukin-6 and Granulocyte Macrophage Colony-Stimulating FactorThe Journal of Infectious Diseases, 2011
- Chikungunya: A Potentially Emerging Epidemic?PLoS Neglected Tropical Diseases, 2010
- A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infectionNature Medicine, 2010
- Present and future arboviral threatsAntiviral Research, 2009
- Prophylaxis and Therapy for Chikungunya Virus InfectionThe Journal of Infectious Diseases, 2009
- Chimeric alphavirus vaccine candidates for chikungunyaVaccine, 2008
- Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virusVaccine, 2008
- Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirusJournal of General Virology, 2007